|
1
|
Bianchini G, Balko JM, Mayer IA, Sanders
ME and Gianni L: Triple-negative breast cancer: Challenges and
opportunities of a heterogeneous disease. Nat Rev Clin Oncol.
13:674–690. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Smid M, Wang Y, Zhang Y, Sieuwerts AM, Yu
J, Klijn JG, Foekens JA and Martens JW: Subtypes of breast cancer
show preferential site of relapse. Cancer Res. 68:3108–3114. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Silver DP, Richardson AL, Eklund AC, Wang
ZC, Szallasi Z, Li Q, Juul N, Leong CO, Calogrias D, Buraimoh A, et
al: Efficacy of neoadjuvant Cisplatin in triple-negative breast
cancer. J Clin Oncol. 28:1145–1153. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Collignon J, Lousberg L, Schroeder H and
Jerusalem G: Triple-negative breast cancer: Treatment challenges
and solutions. Breast Cancer (Dove Med Press. 8:93–107.
2016.PubMed/NCBI
|
|
5
|
O'Shaughnessy J, Osborne C, Pippen JE,
Yoffe M, Patt D, Rocha C, Koo IC, Sherman BM and Bradley C:
Iniparib plus chemotherapy in metastatic triple-negative breast
cancer. N Engl J Med. 364:205–214. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Telli ML, Jensen KC, Vinayak S, Kurian AW,
Lipson JA, Flaherty PJ, Timms K, Abkevich V, Schackmann EA, Wapnir
IL, et al: Phase II study of gemcitabine, carboplatin, and iniparib
as neoadjuvant therapy for triple-negative and BRCA1/2
mutation-associated breast cancer with assessment of a tumor-based
measure of genomic instability: PrECOG 0105. J Clin Oncol.
33:1895–1901. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nanda R, Chow LQ, Dees EC, Berger R, Gupta
S, Geva R, Pusztai L, Pathiraja K, Aktan G, Cheng JD, et al:
Pembrolizumab in patients with advanced triple-negative breast
cancer: Phase Ib KEYNOTE-012 Study. J Clin Oncol. 34:2460–2467.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fumagalli C, Pruneri G, Possanzini P,
Manzotti M, Barile M, Feroce I, Colleoni M, Bonanni B, Maisonneuve
P, Radice P, et al: Methylation of O6-methylguanine-DNA
methyltransferase (MGMT) promoter gene in triple-negative breast
cancer patients. Breast Cancer Res Treat. 134:131–137. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Campone M, Valo I, Jézéquel P, Moreau M,
Boissard A, Campion L, Loussouarn D, Verriele V, Coqueret O and
Guette C: Prediction of recurrence and survival for triple-negative
breast cancer (TNBC) by a protein signature in tissue samples. Mol
Cell Proteomics. 14:2936–2946. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang CQ, Li Y, Huang BF, Zhao YM, Yuan H,
Guo D, Su CM, Hu GN, Wang Q, Long T, et al: EGFR conjunct FSCN1 as
a novel therapeutic strategy in triple-negative breast cancer. Sci
Rep. 7:156542017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Inanc M, Ozkan M, Karaca H, Berk V,
Bozkurt O, Duran AO, Ozaslan E, Akgun H, Tekelioglu F and Elmali F:
Cytokeratin 5/6, c-Met expressions, and PTEN loss prognostic
indicators in triple-negative breast cancer. Med Oncol. 31:8012014.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tutt A, Robson M, Garber JE, Domchek SM,
Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler
RK, et al: Oral poly(ADP-ribose) polymerase inhibitor olaparib in
patients with BRCA1 or BRCA2 mutations and advanced breast cancer:
A proof-of-concept trial. Lancet. 376:235–244. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bianchini G, Balko JM, Mayer IA, Sanders
ME and Gianni L: Triple-negative breast cancer: Challenges and
opportunities of a heterogeneous disease. Nat Rev Clin Oncol.
13:674–690. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Nedeljković M and Damjanović A: Mechanisms
of chemotherapy resistance in triple-negative breast cancer-how we
can rise to the challenge. Cells. 8:9572019. View Article : Google Scholar
|
|
15
|
Curtis C, Shah SP, Chin SF, Turashvili G,
Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, et
al: The genomic and transcriptomic architecture of 2,000 breast
tumours reveals novel subgroups. Nature. 486:346–352. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lehmann BD, Bauer JA, Chen X, Sanders ME,
Chakravarthy AB, Shyr Y and Pietenpol JA: Identification of human
triple-negative breast cancer subtypes and preclinical models for
selection of targeted therapies. J Clin Invest. 121:2750–2767.
2011. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Harano K, Wang Y, Lim B, Seitz RS, Morris
SW, Bailey DB, Hout DR, Skelton RL, Ring BZ, Masuda H, et al: Rates
of immune cell infiltration in patients with triple-negative breast
cancer by molecular subtype. PLoS One. 13:e02045132018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bonsang-Kitzis H, Sadacca B, Hamy-Petit
AS, Moarii M, Pinheiro A, Laurent C and Reyal F: Biological
network-driven gene selection identifies a stromal immune module as
a key determinant of triple-negative breast carcinoma prognosis.
Oncoimmunology. 5:e10611762015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Burstein MD, Tsimelzon A, Poage GM,
Covington KR, Contreras A, Fuqua SA, Savage MI, Osborne CK,
Hilsenbeck SG, Chang JC, et al: Comprehensive genomic analysis
identifies novel subtypes and targets of triple-negative breast
cancer. Clin Cancer Res. 21:1688–1698. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Fumarola C, Petronini PG and Alfieri R:
Impairing energy metabolism in solid tumors through agents
targeting oncogenic signaling pathways. Biochem Pharmacol.
151:114–125. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Spencer NY and Stanton RC: The Warburg
effect, lactate, and nearly a century of trying to cure cancer.
Seminars Nephrol. 39:380–393. 2019. View Article : Google Scholar
|
|
22
|
Schwartz L, Supuran CT and Alfarouk KO:
The Warburg effect and the hallmarks of cancer. Anticancer Agents
Med Chem. 17:164–170. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sonveaux P, Végran F, Schroeder T, Wergin
MC, Verrax J, Rabbani ZN, De Saedeleer CJ, Kennedy KM, Diepart C,
Jordan BF, et al: Targeting lactate-fueled respiration selectively
kills hypoxic tumor cells in mice. J Clin Invest. 118:3930–3942.
2008.PubMed/NCBI
|
|
24
|
Whitaker-Menezes D, Martinez-Outschoorn
UE, Flomenberg N, Birbe RC, Witkiewicz AK, Howell A, Pavlides S,
Tsirigos A, Ertel A, Pestell RG, et al: Hyperactivation of
oxidative mitochondrial metabolism in epithelial cancer cells in
situ: Visualizing the therapeutic effects of metformin in tumor
tissue. Cell Cycle. 10:4047–4064. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Faubert B, Li KY, Cai L, Hensley CT, Kim
J, Zacharias LG, Yang C, Do QN, Doucette S, Burguete D, et al:
Lactate metabolism in human lung tumors. Cell. 171:358–371.e9.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Nieman KM, Kenny HA, Penicka CV, Ladanyi
A, Buell-Gutbrod R, Zillhardt MR, Romero IL, Carey MS, Mills GB,
Hotamisligil GS, et al: Adipocytes promote ovarian cancer
metastasis and provide energy for rapid tumor growth. Nat Med.
17:1498–1503. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Le A, Lane AN, Hamaker M, Bose S, Gouw A,
Barbi J, Tsukamoto T, Rojas CJ, Slusher BS, Zhang H, et al:
Glucose-independent glutamine metabolism via TCA cycling for
proliferation and survival in B cells. Cell Metab. 15:110–121.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Pacheco-Velazquez SC, Robledo-Cadena DX,
Hernandez-Resendiz I, Gallardo-Perez JC, Moreno-Sanchez R and
Rodriguez-Enriquez S: Energy metabolism drugs block triple negative
breast metastatic cancer cell phenotype. Mol Pharm. 15:2151–2164.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kim S, Kim DH, Jung WH and Koo JS:
Metabolic phenotypes in triple-negative breast cancer. Tumour Biol.
34:1699–1712. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Jeon HM, Kim DH, Jung WH and Koo JS:
Expression of cell metabolism-related genes in different molecular
subtypes of triple-negative breast cancer. Tumori. 99:555–564.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Camarda R, Zhou AY, Kohnz RA, Balakrishnan
S, Mahieu C, Anderton B, Eyob H, Kajimura S, Tward A, Krings G, et
al: Inhibition of fatty acid oxidation as a therapy for
MYC-overexpressing triple-negative breast cancer. Nat Med.
22:427–432. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yamashita Y, Nishiumi S, Kono S, Takao S,
Azuma T and Yoshida M: Differences in elongation of very long chain
fatty acids and fatty acid metabolism between triple-negative and
hormone receptor-positive breast cancer. BMC Cancer. 17:5892017.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Jézéquel P, Kerdraon O, Hondermarck H,
Guérin-Charbonnel C, Lasla H, Gouraud W, Canon JL, Gombos A, Dalenc
F and Delaloge S: Gene-expression molecular subtyping of
triple-negative breast cancer tumours: Importance of immune
response. Breast Cancer Res. 17:432015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sabatier R, Finetti P, Cervera N,
Lambaudie E, Esterni B, Mamessier E, Tallet A, Chabannon C, Extra
JM, Jacquemier J, et al: A gene expression signature identifies two
prognostic subgroups of basal breast cancer. Breast Cancer Res
Treat. 126:407–420. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Irizarry RA, Bolstad BM, Collin F, Cope
LM, Hobbs B and Speed TP: Summaries of Affymetrix GeneChip probe
level data. Nucleic Acids Res. 31:e152003. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Haw R and Stein L: Using the reactome
database. Curr Protoc Bioinformatics Chapter 8: Unit8.7. 2012.
View Article : Google Scholar
|
|
37
|
Brunet JP, Tamayo P, Golub TR and Mesirov
JP: Metagenes and molecular pattern discovery using matrix
factorization. Proc Natl Acad Sci USA. 101:4164–4169. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Li T, Fan J, Wang B, Traugh N, Chen Q, Liu
JS, Li B and Liu XS: TIMER: A web server for comprehensive analysis
of tumor-infiltrating immune cells. Cancer Res. 77:e108–e110. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hou JY, Wang YG, Ma SJ, Yang BY and Li QP:
Identification of a prognostic 5-Gene expression signature for
gastric cancer. J Cancer Res Clin Oncol. 143:619–629. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Love MI, Huber W and Anders S: Moderated
estimation of fold change and dispersion for RNA-seq data with
DESeq2. Genome Biol. 15:5502014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Song W, Miao DL and Chen L: Comprehensive
analysis of long noncoding RNA-associated competing endogenous RNA
network in cholangiocarcinoma. Biochem Biophys Res Commun.
506:1004–1012. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Shannon P, Markiel A, Ozier O, Baliga NS,
Wang JT, Ramage D, Amin N, Schwikowski B and Ideker T: Cytoscape: A
software environment for integrated models of biomolecular
interaction networks. Genome Res. 13:2498–2504. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Subramanian A, Tamayo P, Mootha VK,
Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub
TR, Lander ES and Mesirov JP: Gene set enrichment analysis: A
knowledge-based approach for interpreting genome-wide expression
profiles. Proc Natl Acad Sci USA. 102:15545–15550. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Youden WJ: Index for rating diagnostic
tests. Cancer. 3:32–35. 1950. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Xie G, Yang H, Ma D, Sun Y, Chen H, Hu X,
Jiang YZ and Shao ZM: Integration of whole-genome sequencing and
functional screening identifies a prognostic signature for lung
metastasis in triple-negative breast cancer. Int J Cancer.
145:2850–2860. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Lv X, He M, Zhao Y, Zhang L, Zhu W, Jiang
L, Yan Y, Fan Y, Zhao H, Zhou S, et al: Identification of potential
key genes and pathways predicting pathogenesis and prognosis for
triple-negative breast cancer. Cancer Cell Int. 19:1722019.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Quist J, Mirza H, Cheang MCU, Telli ML,
O'Shaughnessy JA, Lord CJ, Tutt ANJ and Grigoriadis A: A Four-gene
decision tree signature classification of Triple-negative breast
cancer: Implications for targeted therapeutics. Mol Cancer Ther.
18:204–212. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Balachandran VP, Gonen M, Smith JJ and
DeMatteo RP: Nomograms in oncology: More than meets the eye. Lancet
Oncol. 16:e173–e180. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Tseng LM, Hsu NC, Chen SC, Lu YS, Lin CH,
Chang DY, Li H, Lin YC, Chang HK, Chao TC, et al: Distant
metastasis in triple-negative breast cancer. Neoplasma. 60:290–294.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Altundag K: Genomic profiling of brain
metastasis and matched primary Triple-negative breast cancer. Clin
Breast Cancer. 17:e1612017. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Abramson VG and Mayer IA: Molecular
heterogeneity of triple negative breast cancer. Curr Br Cancer Rep.
6:154–158. 2014. View Article : Google Scholar
|
|
52
|
Chiu AM, Mitra M, Boymoushakian L and
Coller HA: Integrative analysis of the inter-tumoral heterogeneity
of triple-negative breast cancer. Sci Rep. 8:118072018. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Hashimoto N, Nagano H and Tanaka T: The
role of tumor suppressor p53 in metabolism and energy regulation,
and its implication in cancer and lifestyle-related diseases.
Endocr J. 66:485–496. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Zhu S, Dong Z, Ke X, Hou J, Zhao E, Zhang
K, Wang F, Yang L, Xiang Z and Cui H: The roles of sirtuins family
in cell metabolism during tumor development. Semin Cancer Biol.
57:59–71. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Lu J: The Warburg metabolism fuels tumor
metastasis. Cancer Metastasis Rev. 38:157–164. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Urra FA, Munoz F, Cordova-Delgado M,
Ramírez MP, Peña-Ahumada B, Rios M, Cruz P, Ahumada-Castro U,
Bustos G, Silva-Pavez E, et al: FR58P1a; a new uncoupler of OXPHOS
that inhibits migration in triple-negative breast cancer cells via
Sirt1/AMPK/β1-integrin pathway. Sci Rep. 8:131902018. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Li W, Tanikawa T, Kryczek I, Xia H, Li G,
Wu K, Wei S, Zhao L, Vatan L, Wen B, et al: Aerobic glycolysis
controls myeloid-derived suppressor cells and tumor immunity via a
specific CEBPB isoform in triple-negative breast cancer. Cell
Metab. 28:87–103.e6. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Cserni G, Chmielik E, Cserni B and Tot T:
The new TNM-based staging of breast cancer. Virchows Arch.
472:697–703. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Hortobagyi GN, Edge SB and Giuliano A: New
and important changes in the TNM staging system for breast cancer.
Am Soc Clin Oncol Educ Book. 38:457–467. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Chen YC, Gonzalez ME, Burman B, Zhao X,
Anwar T, Tran M, Medhora N, Hiziroglu AB, Lee W, Cheng YH, et al:
Mesenchymal Stem/Stromal cell engulfment reveals metastatic
advantage in breast cancer. Cell Rep. 27:3916–3926.e5. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Kalantari-Dehaghi M, Parnell EA, Armand T,
Bernard HU and Grando SA: The nicotinic acetylcholine
receptor-mediated reciprocal effects of the tobacco nitrosamine NNK
and SLURP-1 on human mammary epithelial cells. Int Immunopharmacol.
29:99–104. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Zhu L, Ma N, Wang B, Wang L, Zhou C, Yan
Y, He J and Ren Y: Significant prognostic values of aquaporin mRNA
expression in breast cancer. Cancer Manag Res. 11:1503–1515. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Wittliff JL, Sereff SB and Daniels MW:
Expression of genes for methylxanthine pathway-associated enzymes
accompanied by sex steroid receptor status impacts breast carcinoma
progression. Hormones Cancer. 8:298–313. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
de Vega S, Kondo A, Suzuki M, Arai H,
Jiapaer S, Sabit H, Nakada M, Ikeuchi T, Ishijima M,
Arikawa-Hirasawa E, et al: Fibulin-7 is overexpressed in
glioblastomas and modulates glioblastoma neovascularization through
interaction with angiopoietin-1. Int J Cancer. 145:2157–2169. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Celestino R, Nome T, Pestana A, Hoff AM,
Gonçalves AP, Pereira L, Cavadas B, Eloy C, Bjøro T,
Sobrinho-Simões M, et al: CRABP1, C1QL1 and LCN2 are biomarkers of
differentiated thyroid carcinoma, and predict extrathyroidal
extension. BMC Cancer. 18:682018. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Atiakshin D, Buchwalow I, Samoilova V and
Tiemann M: Tryptase as a polyfunctional component of mast cells.
Histochem Cell Biol. 149:461–477. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Aponte-López A, Fuentes-Pananá EM,
Cortes-Muñoz D and Muñoz-Cruz S: Mast cell, the neglected member of
the tumor microenvironment: Role in breast cancer. J Immunol Res.
2018:25842432018. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Yang XP, Li Y, Wang Y, Wang Y and Wang P:
Beta-Tryptase up-regulates vascular endothelial growth factor
expression via proteinase-activated receptor-2 and
mitogen-activated protein kinase pathways in bone marrow stromal
cells in acute myeloid leukemia. Leuk Lymphoma. 51:1550–1558. 2010.
View Article : Google Scholar : PubMed/NCBI
|
